UNSPSC 51144102: Amfepentorex

This classification denotes an anorexiant with the molecular formula C15H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) OPE7BD4AAA, chemically known as phenethylamine, n,alpha-dimethyl-p-pentyl- but more generally known as amfepentorex, which bears US NIH Compound Identifier 71877. European Medicines Agency schedules Amfepentorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05416MIG.

UNSPSC 51144102 Amfepentorex is a Commodity code that encompasses pharmaceutical procurement by state and local health agencies, though recent solicitations under this code show limited activity directly matching the nominal product category. State and local governments procuring under this code are acquiring naloxone (opioid reversal agents), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state agencies, local government facilities, and participating jurisdictions. The procurement mix spans direct purchase of specific health-related pharmaceuticals and devices through IFBs (Invitation for Bid), exploratory RFIs (Request for Information) to gather vendor capabilities for direct-to-manufacturer contracting models, and RFPs establishing multiple-award pharmaceutical supply contracts with authorized wholesalers. Vendors must typically demonstrate FDA compliance, current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) adherence, E-Verify eligibility, drug-free workplace certification, and specified insurance coverage including commercial general liability and professional liability.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with responses due March 26, 2026 and contract effectiveness July 1, 2026. Pricing evaluation under MMCAP weighted price competitiveness at 75 percent, with vendors required to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, Morris & Dickson Co.).